Iguratimod attenuated fibrosis in systemic sclerosis via targeting early growth response 1 expression

BACKGROUND: The early growth response 1 (EGR1) is a central transcription factor involved in systemic sclerosis (SSc) pathogenesis. Iguratimod is a synthesized anti-rheumatic disease-modifying drug, which shows drastic inhibition to EGR1 expression in B cells. This study is aiming to investigate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Lichong, Yin, Hanlin, Sun, Li, Zhang, Zhiliang, Jin, Yuyang, Cao, Shan, Fu, Qiong, Fan, Chaofan, Bao, Chunde, Lu, Liangjing, Zhan, Yifan, Xu, Xiaojiang, Chen, Xiaoxiang, Yan, Qingran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439582/
https://www.ncbi.nlm.nih.gov/pubmed/37596660
http://dx.doi.org/10.1186/s13075-023-03135-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439582/
https://www.ncbi.nlm.nih.gov/pubmed/37596660
http://dx.doi.org/10.1186/s13075-023-03135-2

Ejemplares similares